Literature DB >> 9120527

The importance of histologic type on breast cancer survival.

M E Northridge1, G G Rhoads, D Wartenberg, D Koffman.   

Abstract

Breast cancer is a morphologically and genetically heterogeneous disease. The Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute provides the large number of cases necessary to study individual histologic types of female invasive breast cancer that for practical reasons are otherwise unattainable. Attention was specifically focused on 4082 cases of mucinous adenocarcinoma and 139,154 cases of infiltrating duct carcinoma identified for the years 1973-1990. Life table analyses were conducted to compare survival by histologic type using death due to breast cancer as the outcome; Cox proportional hazards analysis was used to adjust for important covariates. Findings were that women diagnosed with mucinous adenocarcinoma have a rate of mortality due to breast cancer that is 0.38 that of the rate of women diagnosed with infiltrating duct carcinoma (95% confidence interval 0.34-0.42). We conclude that histologic type is important to consider in the prognosis and treatment of women diagnosed with breast cancer.

Entities:  

Mesh:

Year:  1997        PMID: 9120527     DOI: 10.1016/s0895-4356(96)00366-6

Source DB:  PubMed          Journal:  J Clin Epidemiol        ISSN: 0895-4356            Impact factor:   6.437


  11 in total

1.  Cancerous breast lesions on dynamic contrast-enhanced MR images: computerized characterization for image-based prognostic markers.

Authors:  Neha Bhooshan; Maryellen L Giger; Sanaz A Jansen; Hui Li; Li Lan; Gillian M Newstead
Journal:  Radiology       Date:  2010-02-01       Impact factor: 11.105

Review 2.  Protein biomarkers for subtyping breast cancer and implications for future research.

Authors:  Claudius Mueller; Amanda Haymond; Justin B Davis; Alexa Williams; Virginia Espina
Journal:  Expert Rev Proteomics       Date:  2018-01-03       Impact factor: 3.940

3.  Resistance to trastuzumab in HER2-positive mucinous invasive ductal breast carcinoma.

Authors:  Zora Baretta; Rodrigo Santa Cruz Guindalini; Galina Khramtsova; Olufunmilayo I Olopade
Journal:  Clin Breast Cancer       Date:  2012-12-29       Impact factor: 3.225

4.  Rare breast cancer subtypes: histological, molecular, and clinical peculiarities.

Authors:  Maria Vittoria Dieci; Enrico Orvieto; Massimo Dominici; PierFranco Conte; Valentina Guarneri
Journal:  Oncologist       Date:  2014-06-26

5.  Expression of metalloproteases and their inhibitors in different histological types of breast cancer.

Authors:  J M Del Casar; S González-Reyes; L O González; J M González; S Junquera; M Bongera; M F García; A Andicoechea; C Serra; F J Vizoso
Journal:  J Cancer Res Clin Oncol       Date:  2009-11-15       Impact factor: 4.553

Review 6.  An overview of prognostic factors for long-term survivors of breast cancer.

Authors:  Isabelle Soerjomataram; Marieke W J Louwman; Jacques G Ribot; Jan A Roukema; Jan Willem W Coebergh
Journal:  Breast Cancer Res Treat       Date:  2007-03-22       Impact factor: 4.872

7.  Clinical Nomogram for Predicting Survival Outcomes in Early Mucinous Breast Cancer.

Authors:  Jianfei Fu; Lunpo Wu; Mengjie Jiang; Dan Li; Ting Jiang; Zhongwu Hong; Fan Wang; Shuguang Li
Journal:  PLoS One       Date:  2016-10-19       Impact factor: 3.240

8.  The prognosis of invasive micropapillary carcinoma compared with invasive ductal carcinoma in the breast: a meta-analysis.

Authors:  Yun Wu; Ning Zhang; Qifeng Yang
Journal:  BMC Cancer       Date:  2017-12-11       Impact factor: 4.430

9.  Impact of false-positive mammography on subsequent screening attendance and risk of cancer.

Authors:  Jenny McCann; Diane Stockton; Sara Godward
Journal:  Breast Cancer Res       Date:  2002-07-17       Impact factor: 6.466

10.  Prognostic value of morphology and hormone receptor status in breast cancer - a population-based study.

Authors:  C Allemani; M Sant; F Berrino; T Aareleid; G Chaplain; J W Coebergh; M Colonna; P Contiero; A Danzon; M Federico; L Gafà; P Grosclaude; G Hédelin; J Macè-Lesech; C M Garcia; E Paci; N Raverdy; B Tretarre; E M I Williams
Journal:  Br J Cancer       Date:  2004-10-04       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.